ACAD Stock Soared to a Four-Month High.
Acadia Pharmaceuticals shares are trading higher Wednesday after the company won summary judgement in a patent suit. Just then Acadia Surged upto 33% in regards to the news.
Acadia Pharmaceuticals (ACAD) notched a win in a patent battle Wednesday pertaining to its Parkinson's drug, Nuplazid. ACAD stock soared to a four-month high.
ACAD Stock: Cashing In On Nuplazid
Nuplazid is an important drug for Acadia. It's currently approved to treat patients with psychosis due to Parkinson's disease. In the September quarter, Nuplazid brought in $144.8 million in sales, accounting for more than 68% of total sales.
ACAD is trading above the 50, 100, & 200-day moving average indicating a Bullish Bias.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.